MD – University of New South Wales – Australia
Go further with Phil Barter’s video interviews below
Philip Barter is the immediate past President of the International Atherosclerosis Society. He graduated in medicine from the University of Adelaide and gained his PhD from the Australian National University. He has held positions in research institutes and universities in Australia and the US and is currently based at the University of New South Wales in Australia. He is a fellow of the Royal Australasian College of Physicians. His basic research interests are plasma lipids and lipoproteins, specifically high density lipoproteins, the factors that regulate them and the mechanism by which they protect against cardiovascular disease. His clinical research involves participation in clinical trials of lipid-lowering agents. He is currently a member of the steering committees of the REVEAL HPS-3 TIMI-55 trial and the ACCELERATE trial. He has published more than 350 peer-reviewed research papers on plasma lipids and lipoproteins, their metabolism, regulation, function and relationship to atherosclerosis. He has also written handbooks on HDL and CETP inhibitors.
SOURCE : ozheart
Go further with Phil Barter
What should be the ideal trials for HDL?